---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-21-024665"
form_type: "8-K"
ticker: "PTIX"
cik: "0001022899"
company_name: "Protagenic Therapeutics, Inc.new"
filed_at: "2021-10-05T23:59:59+00:00"
generated_at: "2026-06-28T22:48:39.384767+00:00"
event_type: "regulatory"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Protagenic Therapeutics resolves Nasdaq audit committee compliance issue, appoints Joshua Silverman

## Summary
- Nasdaq notified the Company of audit committee composition non-compliance from April 27 to September 30, 2021.
- Dr. Jennifer Buell resigned from the Audit Committee; Joshua Silverman appointed effective October 1, 2021.
- With Silverman's appointment, the Company is now in compliance with Nasdaq Listing Rule 5605(c)(2)(A).
- It was later determined that Dr. Buell met independence requirements; she remains an independent board member.

## SEC filing metadata
- accession: 0001493152-21-024665
- form_type: 8-K
- ticker: PTIX
- cik: 0001022899
- company_name: Protagenic Therapeutics, Inc.new
- filed_at: 2021-10-05T23:59:59+00:00
- event_type: regulatory
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1022899/000149315221024665/0001493152-21-024665-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1022899/000149315221024665/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-21-024665
- JSON: https://secwatch.observer/filing/0001493152-21-024665.json
- Plain text: https://secwatch.observer/filing/0001493152-21-024665.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.